Gunnar B. Kristensen
About
Gunnar B. Kristensen is a scholar working on Reproductive Medicine, Obstetrics and Gynecology and Oncology.
According to data from OpenAlex, Gunnar B. Kristensen has authored 266 papers receiving a total of 14.7k indexed citations (citations by other indexed papers that have themselves been cited), including 118 papers in Reproductive Medicine, 83 papers in Obstetrics and Gynecology and 69 papers in Oncology. Recurrent topics in Gunnar B. Kristensen's work include Ovarian cancer diagnosis and treatment (115 papers), Endometrial and Cervical Cancer Treatments (81 papers) and Cervical Cancer and HPV Research (40 papers). Gunnar B. Kristensen is often cited by papers focused on Ovarian cancer diagnosis and treatment (115 papers), Endometrial and Cervical Cancer Treatments (81 papers) and Cervical Cancer and HPV Research (40 papers). Gunnar B. Kristensen collaborates with scholars based in Norway, Switzerland and United Kingdom. Gunnar B. Kristensen's co-authors include Vera M. Abeler, Claes G. Tropé, Ignace Vergote, Ruth Holm, Claes G. Tropé, Éric Pujade-Lauraine, Jahn M. Nesland, M. Baekelandt, Ben Davidson and Corneel Coens and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.
In The Last Decade
Gunnar B. Kristensen
264 papers receiving 14.4k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Gunnar B. Kristensen Norway | 59 | 7.6k | 4.4k | 4.3k | 3.8k | 3.6k | 266 | 14.7k | ||
| Robert A. Burger United States | 48 | 9.1k 1.2× | 3.7k 0.8× | 4.6k 1.1× | 4.4k 1.2× | 3.6k 1.0× | 202 | 14.8k | ||
| Karl C. Podratz United States | 67 | 7.2k 0.9× | 7.2k 1.6× | 3.0k 0.7× | 3.5k 0.9× | 2.4k 0.7× | 264 | 13.9k | ||
| Nicoletta Colombo Italy | 66 | 10.7k 1.4× | 6.0k 1.4× | 7.3k 1.7× | 4.3k 1.1× | 3.3k 0.9× | 451 | 18.3k | ||
| Carol Aghajanian United States | 62 | 7.5k 1.0× | 4.3k 1.0× | 6.1k 1.4× | 3.2k 0.9× | 3.6k 1.0× | 425 | 15.3k | ||
| C. Blake Gilks Canada | 75 | 7.2k 0.9× | 6.3k 1.4× | 4.6k 1.1× | 1.9k 0.5× | 4.6k 1.3× | 291 | 16.7k | ||
| Ross S. Berkowitz United States | 66 | 5.4k 0.7× | 2.9k 0.7× | 2.7k 0.6× | 2.4k 0.6× | 4.6k 1.3× | 445 | 18.7k | ||
| John K. Chan United States | 60 | 5.1k 0.7× | 3.7k 0.8× | 4.1k 0.9× | 2.9k 0.8× | 1.9k 0.5× | 277 | 11.9k | ||
| Jonathan A. Ledermann United Kingdom | 60 | 8.0k 1.1× | 2.7k 0.6× | 9.2k 2.1× | 3.1k 0.8× | 4.9k 1.4× | 295 | 17.4k | ||
| Ana Oaknin Spain | 39 | 4.4k 0.6× | 3.2k 0.7× | 6.8k 1.6× | 1.8k 0.5× | 3.8k 1.1× | 320 | 12.7k | ||
| Sandro Pignata Italy | 51 | 4.2k 0.6× | 2.0k 0.4× | 4.4k 1.0× | 2.4k 0.6× | 2.4k 0.7× | 434 | 10.6k |
Countries citing papers authored by Gunnar B. Kristensen
Since
Specialization
Citations
This map shows the geographic impact of Gunnar B. Kristensen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gunnar B. Kristensen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gunnar B. Kristensen more than expected).
Fields of papers citing papers by Gunnar B. Kristensen
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Gunnar B. Kristensen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gunnar B. Kristensen. The network helps show where Gunnar B. Kristensen may publish in the future.
Co-authorship network of co-authors of Gunnar B. Kristensen
This figure shows the co-authorship network connecting the top 25 collaborators of Gunnar B. Kristensen. A scholar is included among the top collaborators of Gunnar B. Kristensen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gunnar B. Kristensen. Gunnar B. Kristensen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Lindemann, Kristina, Wanja Kildal, Andreas Kleppe, et al.. (2024). Real-world outcomes in molecular subgroups for patients with advanced or recurrent endometrial cancer treated with platinum-based chemotherapy. International Journal of Gynecological Cancer. 35(5). 101618–101618.
2.
Lindemann, Kristina, Milada Cvancarova Småstuen, Kjersti Bruheim, et al.. (2021). Salvage Radiation for Pelvic Relapse after Surgically Treated Endometrial Cancer. Cancers. 13(6). 1367–1367.
3.
Hompland, Tord, Christina S. Fjeldbo, Eva‐Katrine Aarnes, et al.. (2020). MRI Distinguishes Tumor Hypoxia Levels of Different Prognostic and Biological Significance in Cervical Cancer. Cancer Research. 80(18). 3993–4003.
4.
Binzer-Panchal, Amrei, Mehran Ghaderi, Tjalling Bosse, et al.. (2019). Integrated Molecular Analysis of Undifferentiated Uterine Sarcomas Reveals Clinically Relevant Molecular Subtypes. Clinical Cancer Research. 25(7). 2155–2165.
5.
Vergote, Ignace, Corneel Coens, Matthew Nankivell, et al.. (2019). Neoadjuvant Chemotherapy Versus Debulking Surgery in Advanced Tubo-Ovarian Cancers: Pooled Analysis of Individual Patient Data From the EORTC 55971 and CHORUS Trials. Obstetrical & Gynecological Survey. 74(3). 156–158.
6.
Lindemann, Kristina, Emma Gibbs, Elisabeth Åvall‐Lundqvist, et al.. (2017). Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist). British Journal of Cancer. 116(4). 455–463.
7.
Fjeldbo, Christina S., Cathinka Halle, Malin Lando, et al.. (2016). Integrative Analysis of DCE-MRI and Gene Expression Profiles in Construction of a Gene Classifier for Assessment of Hypoxia-Related Risk of Chemoradiotherapy Failure in Cervical Cancer. Clinical Cancer Research. 22(16). 4067–4076.
8.
Pujade-Lauraine, Éric, Felix Hilpert, B. Weber, et al.. (2014). Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial. Journal of Clinical Oncology. 32(13). 1302–1308.
9.
Pujade-Lauraine, Éric, Felix Hilpert, B. Weber, et al.. (2014). Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer. Obstetrical & Gynecological Survey. 69(7). 402–404.
10.
Halle, Cathinka, Erlend Andersen, Malin Lando, et al.. (2012). Hypoxia-Induced Gene Expression in Chemoradioresistant Cervical Cancer Revealed by Dynamic Contrast-Enhanced MRI. Cancer Research. 72(20). 5285–5295.
11.
Halle, Cathinka, Malin Lando, Debbie Hege Svendsrud, et al.. (2011). Membranous Expression of Ectodomain Isoforms of the Epidermal Growth Factor Receptor Predicts Outcome after Chemoradiotherapy of Lymph Node–Negative Cervical Cancer. Clinical Cancer Research. 17(16). 5501–5512.
12.
Kildal, Wanja, Francesca Micci, Bjørn Risberg, et al.. (2011). Genomic imbalances in endometrial adenocarcinomas — Comparison of DNA ploidy, karyotyping and comparative genomic hybridization. Molecular Oncology. 6(1). 98–107.
13.
Pujade-Lauraine, Éric, Uwe Wagner, Val Gebski, et al.. (2010). Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse. Journal of Clinical Oncology. 28(20). 3323–3329.
14.
Perren, Timothy, Jacobus Pfisterer, JA Ledermann, et al.. (2010). ICON7: A PHASE III RANDOMISED GYNAECOLOGIC CANCER INTERGROUP TRIAL OF CONCURRENT BEVACIZUMAB AND CHEMOTHERAPY FOLLOWED BY MAINTENANCE BEVACIZUMAB, VERSUS CHEMOTHERAPY ALONE IN WOMEN WITH NEWLY DIAGNOSED EPITHELIAL OVARIAN (EOC), PRIMARY PERITONEAL (PPC) OR FALLOPIAN TUBE CANCER (FTC). UCL Discovery (University College London).
15.
Davidson, Ben, Virginia Espina, Seth M. Steinberg, et al.. (2006). Proteomic Analysis of Malignant Ovarian Cancer Effusions as a Tool for Biologic and Prognostic Profiling. Clinical Cancer Research. 12(3). 791–799.
16.
Kildal, Wanja, Sigrid Marie Kraggerud, Vera M. Abeler, et al.. (2003). Genome profiles of bilateral dysgerminomas, a unilateral gonadoblastoma, and a metastasis from a 46, XY phenotypic female. Human Pathology. 34(9). 946–949.
17.
Vergote, Ignace, et al.. (2002). First line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel-epirubicin-carboplatin (TEC) vs paclitaxel-carboplatin (TC). Interim results of an NSGO-EORTC GCG - NCIC CTG intergroup Phase III study. International Journal of Gynecological Cancer. 12(5).
18.
Kristensen, Gunnar B., Wanja Kildal, Renate Pettersen, et al.. (2000). High-resolution Image Analysis - A Better Method for Predicting Prognosis in Early Ovarian Cancer. Gynecologic Oncology. 76(2). 236–236.
19.
Marth, Christian, et al.. (1998). Ten-year results of a randomised trial comparing cisplatin with cisplatin and cyclophosphamide in advanced, suboptimally debulked ovarian cancer. European Journal of Cancer. 34(8). 1175–1180.
20.
Lind, K, et al.. (1985). Importance of Mycoplasma hominis in acute salpingitis assessed by culture and serological tests.. Sexually Transmitted Infections. 61(3). 185–189.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Robert A. Burger Breakdown of academic impact, for papers by Karl C. Podratz Breakdown of academic impact, for papers by Nicoletta Colombo Breakdown of academic impact, for papers by Carol Aghajanian Breakdown of academic impact, for papers by C. Blake Gilks Breakdown of academic impact, for papers by Ross S. Berkowitz Breakdown of academic impact, for papers by John K. Chan Breakdown of academic impact, for papers by Jonathan A. Ledermann Breakdown of academic impact, for papers by Ana Oaknin Breakdown of academic impact, for papers by Sandro Pignata